Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contezolid Acefosamil and Contezolid vs Linezolid in Diabetic Foot Infections
NCT05369052Phase 3Recruiting
- Sponsor
- MicuRx Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of contezolid acefosamil, contezolid in diabetic foot infection (DFI), sponsored by MicuRx Pharmaceuticals. Started May 2022; status: recruiting.
02
Drugs
contezolid acefosamilcontezolid
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on NCT05369052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369052.